These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 30807553)

  • 21. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
    Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
    Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting Notch1 and proteasome as an effective strategy to suppress T-cell lymphoproliferative neoplasms.
    Yang L; Zhang S; George SK; Teng R; You X; Xu M; Liu H; Sun X; Amin HM; Shi W
    Oncotarget; 2015 Jun; 6(17):14953-69. PubMed ID: 25879451
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death.
    Kashyap T; Argueta C; Aboukameel A; Unger TJ; Klebanov B; Mohammad RM; Muqbil I; Azmi AS; Drolen C; Senapedis W; Lee M; Kauffman M; Shacham S; Landesman Y
    Oncotarget; 2016 Nov; 7(48):78883-78895. PubMed ID: 27713151
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
    Kim A; Seong KM; Kang HJ; Park S; Lee SS
    Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression.
    De Smedt E; Maes K; Verhulst S; Lui H; Kassambara A; Maes A; Robert N; Heirman C; Cakana A; Hose D; Breckpot K; van Grunsven LA; De Veirman K; Menu E; Vanderkerken K; Moreaux J; De Bruyne E
    Cancer Res; 2018 Mar; 78(5):1155-1168. PubMed ID: 29259009
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bortezomib-mediated down-regulation of telomerase and disruption of telomere homeostasis contributes to apoptosis of malignant cells.
    Ci X; Li B; Ma X; Kong F; Zheng C; Björkholm M; Jia J; Xu D
    Oncotarget; 2015 Nov; 6(35):38079-92. PubMed ID: 26472030
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The previously uncharacterized lncRNA APP promotes prostate cancer progression by acting as a competing endogenous RNA.
    Shi X; Zhang W; Nian X; Lu X; Li Y; Liu F; Wang F; He B; Zhao L; Zhu Y; Ren S; Sun Y
    Int J Cancer; 2020 Jan; 146(2):475-486. PubMed ID: 31107971
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Suppression of BRCA1 sensitizes cells to proteasome inhibitors.
    Gu Y; Bouwman P; Greco D; Saarela J; Yadav B; Jonkers J; Kuznetsov SG
    Cell Death Dis; 2014 Dec; 5(12):e1580. PubMed ID: 25522274
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
    Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
    Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Mechanism of action and determinants of sensitivity to the proteasome inhibitor bortezomib in multiple myeloma therapy].
    Ri M
    Rinsho Ketsueki; 2016 May; 57(5):537-45. PubMed ID: 27263777
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
    Zhang X; Wang Y; Ning Y
    Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Involvement of aberrantly activated HOTAIR/EZH2/miR-193a feedback loop in progression of prostate cancer.
    Ling Z; Wang X; Tao T; Zhang L; Guan H; You Z; Lu K; Zhang G; Chen S; Wu J; Qian J; Liu H; Xu B; Chen M
    J Exp Clin Cancer Res; 2017 Nov; 36(1):159. PubMed ID: 29141691
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proteasome inhibition induces IKK-dependent interleukin-8 expression in triple negative breast cancer cells: Opportunity for combination therapy.
    Uddin MM; Zou Y; Sharma T; Gatla HR; Vancurova I
    PLoS One; 2018; 13(8):e0201858. PubMed ID: 30089134
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells.
    Tsapakidis K; Vlachostergios PJ; Voutsadakis IA; Befani CD; Patrikidou A; Hatzidaki E; Daliani DD; Moutzouris G; Liakos P; Papandreou CN
    Int J Urol; 2012 Jun; 19(6):565-74. PubMed ID: 22324515
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HnRNP-L promotes prostate cancer progression by enhancing cell cycling and inhibiting apoptosis.
    Zhou X; Li Q; He J; Zhong L; Shu F; Xing R; Lv D; Lei B; Wan B; Yang Y; Wu H; Mao X; Zou Y
    Oncotarget; 2017 Mar; 8(12):19342-19353. PubMed ID: 28038443
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MicroRNA-466 inhibits tumor growth and bone metastasis in prostate cancer by direct regulation of osteogenic transcription factor RUNX2.
    Colden M; Dar AA; Saini S; Dahiya PV; Shahryari V; Yamamura S; Tanaka Y; Stein G; Dahiya R; Majid S
    Cell Death Dis; 2017 Jan; 8(1):e2572. PubMed ID: 28125091
    [TBL] [Abstract][Full Text] [Related]  

  • 37. C/EBPβ regulates sensitivity to bortezomib in prostate cancer cells by inducing REDD1 and autophagosome-lysosome fusion.
    Barakat DJ; Mendonca J; Barberi T; Zhang J; Kachhap SK; Paz-Priel I; Friedman AD
    Cancer Lett; 2016 May; 375(1):152-161. PubMed ID: 26968249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The NF-κB subunit RelB regulates the migration and invasion abilities and the radio-sensitivity of prostate cancer cells.
    Wang J; Yi S; Zhou J; Zhang Y; Guo F
    Int J Oncol; 2016 Jul; 49(1):381-92. PubMed ID: 27121503
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estrogen induces androgen-repressed SOX4 expression to promote progression of prostate cancer cells.
    Yang M; Wang J; Wang L; Shen C; Su B; Qi M; Hu J; Gao W; Tan W; Han B
    Prostate; 2015 Sep; 75(13):1363-75. PubMed ID: 26015225
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effects of PSMB5 on proliferation and bortezomib chemo-resistance in human myeloma cells and its related molecular mechanisms].
    Mo HM; Wu QY; Han DY; Liu R; Ma X; Zhou P; Xu KL
    Zhonghua Xue Ye Xue Za Zhi; 2017 Dec; 38(12):1053-1057. PubMed ID: 29365400
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.